Company · founded 2014
Meissa Vaccines (United States)
South San Francisco, United States · meissavaccines.com
- Citations, last 5 years
- 114
- Works, last 5 years
- 5
- h-index
- 16
- Scientists listed
- 2
- Grants since 2016
- 6
Grants received
2019–2020 · research · R34
A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Novel Live Attenuated Respiratory Syncytial Virus Vaccine with Thermal Stable Fusion protein in Seropositive Adults and Children
Karen S Slobod · Meissa Vaccines (United States) · funded by National Institutes of Health
2018–2019 · research · R56
Rationally designed live attenuated RSV vaccines
Martin Lawrence Moore · Meissa Vaccines (United States) · funded by National Institutes of Health
2017–2018 · research · R43
Development of polyvalent inactivated rhinovirus vaccine
Martin Lawrence Moore · Meissa Vaccines (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein
Martin Lawrence Moore · Meissa Vaccines (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein
Martin Lawrence Moore · Meissa Vaccines (United States) · funded by National Institutes of Health
2017–2018 · research · R44
Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein
Martin Lawrence Moore · Meissa Vaccines (United States) · funded by National Institutes of Health
